Skip to main content

Table 3 Visual function questionnaire-25 score

From: Safety and efficacy of Razumab™ (world’s first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study

VFQ-25 Score ITT population (N = 125) PP population (N = 116)
Baseline, mean ± SD 60.9 ± 14.36 60.4 ± 14.14
Week 12, mean ± SD 66.7 ± 12.65 66.5 ± 12.50
Mean ± SD change from baseline to Week 12 5.8 ± 10.78 [p < 0.001] 6.1 ± 10.96 [p < 0.001]
Week 24, mean ± SD 69.5 ± 12.46 69.5 ± 12.35
Mean ± SD change from baseline to Week 24 8.5 ± 13.04 [p < 0.001] 9.2 ± 13.33 [p < 0.001]
  1. ITT intent-to-treat population, PP per-protocol population